Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Authors:
- Boglarka GyurkoczaBGBoglarka Gyurkocza
- Hannah ChoeHCHannah Choe
- Stuart E. SeropianSSStuart E. Seropian
- Patrick StiffPSPatrick Stiff
- Edward AguraEAEdward Agura
- Sunil AbhyankarSASunil Abhyankar
- Mark R. LitzowMLMark R. Litzow
- Benjamin TomlinsonBTBenjamin Tomlinson
- Camille AbboudCACamille Abboud
- George L ChenGCGeorge L Chen
- Parameswaran HariPHParameswaran Hari
Open Access
- 1 March 2021
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 27 (3) , S56